PT1

PT1

CAT N°: 21335
Price:

From 55.00 46.75

PT1 is an activator of AMP-activated protein kinase (AMPK) that directly activates the inactive truncated forms of AMPK monomers ?1335, ?1394, and ?2398 in a dose-dependent manner (EC50s = ~ 8, 8, and 12 µM, respectively).{33404} It stimulates the ?1?1?1 AMPK heterotrimer with an EC50 value of 0.3 ?M.{33404} PT1 dose-dependently increases phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase, without increasing the cellular AMP:ATP ratio in L6 myotubes.{33404} In HepG2 liver cells, PT1 lowers lipid content through AMPK activation. PT1 induces autophagy in cardiomyocytes after oxygen glucose deprivation/reoxygenation, resulting in improved cell survival.{33403}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-chloro-5-[[5-[[5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-benzoic acid
  • Correlated keywords
    • PT-1 AMP-activated protein kinase AMPK heterotrimer a1-335 a1-394 a2-398 ?1-335 ?1-394 ?2-398 a1335 a1394 a2398 ?1335 ?1394 ?2398 a1-b1-y1 ?1-?1-?1phosphorylation acetyl-CoA carboxylase AMP:ATP L6 myotubes HepG2 Hep-G2
  • Product Overview:
    PT1 is an activator of AMP-activated protein kinase (AMPK) that directly activates the inactive truncated forms of AMPK monomers ?1335, ?1394, and ?2398 in a dose-dependent manner (EC50s = ~ 8, 8, and 12 µM, respectively).{33404} It stimulates the ?1?1?1 AMPK heterotrimer with an EC50 value of 0.3 ?M.{33404} PT1 dose-dependently increases phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase, without increasing the cellular AMP:ATP ratio in L6 myotubes.{33404} In HepG2 liver cells, PT1 lowers lipid content through AMPK activation. PT1 induces autophagy in cardiomyocytes after oxygen glucose deprivation/reoxygenation, resulting in improved cell survival.{33403}

We also advise you